Načítá se...
Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
BACKGROUND: Fingolimod (FTY) and dimethyl fumarate (DMF) are multiple sclerosis (MS) oral therapies that became available in 2010 and 2013, respectively. OBJECTIVE: The objective of this article is to compare discontinuation rates, efficacy, and adverse events (AEs) of FTY and DMF over two years. ME...
Uloženo v:
| Vydáno v: | Mult Scler J Exp Transl Clin |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5564884/ https://ncbi.nlm.nih.gov/pubmed/28839949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217317725102 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|